A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 1/2 Study to Evaluate AHB-137 Injection Followed by TVAX-008 Injection in Participants With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogs
Sponsor study identifier
interventional
105
0 countries
N/A
Study Start
October 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
September 22, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 20, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 20, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 13, 2026
Actual (reported)October 27, 2026
Actual (reported)October 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 22, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 20, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) in Phase I
Treatment-emergent adverse events (TEAEs) will be assessed during the protocol-defined observation period. The percentage of participants experiencing at least one TEAE will be reported.
From the first dose of study treatment through the last study visit (up to Week 72)
Percentage of Participants Achieving Clinical Cure (Functional Cure) at 24 Weeks After Discontinuation of All Chronic Hepatitis B Treatments in Phase II
Clinical cure is defined as HBsAg clearance (\<0.05 IU/mL) and sustained HBV DNA suppression (\<LLOQ), allowing transient viral rebound, at 24 weeks after discontinuation of all CHB treatments, regardless of HBsAb status. The percentage of participants achieving clinical cure will be reported.
24 weeks after discontinuation of all chronic hepatitis B treatments (up to Week 72)
AHB-137 will be administered per 1 week
Guiqiang Wang
Peking University First Hospital
Yan Wang
Peking University First Hospital
First Submitted
October 13, 2026
First Posted
October 27, 2026
Study Start
October 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
September 22, 2028
AHB-137 will be administered per 1 week
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 20, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 27, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: